Roflumilast for dermatitis, seborrheic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 8 Jul 2021: Trial started, NCT04973228
  2. 22 Jul 2021: Trial registered, NCT04973228
  3. 6 Jul 2026: Trial registered, NCT07683806
  4. 12 Nov 2026: Trial started, NCT07683806

The trials

NCT04445987: Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

State
Completed
Phase
Phase 2
People
408 taking part
Started
12 Jun 2020
Primary completion
19 Nov 2022
Arms
Long-term safety of ARQ-154
Results
Posted on the registry
  1. 12 Jun 2020: Trial started
  2. 24 Jun 2020: Trial registered
  3. 19 Nov 2022: Trial completed
  4. 11 Jun 2024: Trial results posted

NCT04973228: Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

State
Completed
Phase
Phase 3
People
457 taking part
Started
8 Jul 2021
Primary completion
6 Apr 2022
Arms
Roflumilast Foam 0.3%
Results
Posted on the registry
  1. 8 Jul 2021: Trial started
  2. 22 Jul 2021: Trial registered
  3. 6 Apr 2022: Trial completed
  4. 12 Mar 2024: Trial results posted

NCT07683806: Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

State
Under way
Phase
Phase 3
People
309 planned
Started
12 Nov 2026
Primary completion
30 Jun 2027
Arms
Roflumilast foam 0.3%
Results
None posted
  1. 6 Jul 2026: Trial registered
  2. 12 Nov 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as ARQ-154, Daliresp, Daxas, Roflumilast Foam, Roflumilast Foam 0.3%, Zoryve.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.